vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and PARK AEROSPACE CORP (PKE). Click either name above to swap in a different company.

PARK AEROSPACE CORP is the larger business by last-quarter revenue ($17.3M vs $11.0M, roughly 1.6× C4 Therapeutics, Inc.). PARK AEROSPACE CORP runs the higher net margin — 17.0% vs -186.0%, a 203.0% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 20.3%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 3.0%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Park Electrochemical Corp, now called the Park Aerospace Corp, is a Melville, New York-based materials manufacturer for the telecommunications, Internet infrastructure, high-end computing, and aerospace industries. It produces high-technology digital and radio frequency(RF)/microwave printed circuit material products, composite materials. Its printed circuit materials are used for complex multilayer printed circuit boards and other electronic interconnection systems, such as multilayer back-p...

CCCC vs PKE — Head-to-Head

Bigger by revenue
PKE
PKE
1.6× larger
PKE
$17.3M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+92.5% gap
CCCC
112.8%
20.3%
PKE
Higher net margin
PKE
PKE
203.0% more per $
PKE
17.0%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
3.0%
PKE

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
CCCC
CCCC
PKE
PKE
Revenue
$11.0M
$17.3M
Net Profit
$-20.5M
$3.0M
Gross Margin
34.1%
Operating Margin
-210.1%
21.0%
Net Margin
-186.0%
17.0%
Revenue YoY
112.8%
20.3%
Net Profit YoY
40.7%
87.1%
EPS (diluted)
$-0.09
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
PKE
PKE
Q4 25
$11.0M
$17.3M
Q3 25
$11.2M
$16.4M
Q2 25
$6.5M
$15.4M
Q1 25
$7.2M
$16.9M
Q4 24
$5.2M
$14.4M
Q3 24
$15.4M
$16.7M
Q2 24
$12.0M
$14.0M
Q1 24
$3.0M
$16.3M
Net Profit
CCCC
CCCC
PKE
PKE
Q4 25
$-20.5M
$3.0M
Q3 25
$-32.2M
$2.4M
Q2 25
$-26.0M
$2.1M
Q1 25
$-26.3M
$1.2M
Q4 24
$-34.6M
$1.6M
Q3 24
$-24.7M
$2.1M
Q2 24
$-17.7M
$993.0K
Q1 24
$-28.4M
$2.7M
Gross Margin
CCCC
CCCC
PKE
PKE
Q4 25
34.1%
Q3 25
31.2%
Q2 25
30.6%
Q1 25
29.3%
Q4 24
26.6%
Q3 24
28.5%
Q2 24
29.3%
Q1 24
27.3%
Operating Margin
CCCC
CCCC
PKE
PKE
Q4 25
-210.1%
21.0%
Q3 25
-306.4%
17.4%
Q2 25
-441.0%
15.7%
Q1 25
-402.9%
16.8%
Q4 24
-728.4%
12.8%
Q3 24
-183.9%
15.7%
Q2 24
-178.6%
14.9%
Q1 24
-1060.2%
15.7%
Net Margin
CCCC
CCCC
PKE
PKE
Q4 25
-186.0%
17.0%
Q3 25
-286.4%
14.7%
Q2 25
-402.6%
13.5%
Q1 25
-363.7%
7.4%
Q4 24
-667.8%
10.9%
Q3 24
-160.6%
12.4%
Q2 24
-147.6%
7.1%
Q1 24
-933.2%
16.3%
EPS (diluted)
CCCC
CCCC
PKE
PKE
Q4 25
$-0.09
$0.15
Q3 25
$-0.44
$0.12
Q2 25
$-0.37
$0.10
Q1 25
$-0.37
$0.06
Q4 24
$-0.50
$0.08
Q3 24
$-0.35
$0.10
Q2 24
$-0.26
$0.05
Q1 24
$-0.41
$0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
PKE
PKE
Cash + ST InvestmentsLiquidity on hand
$74.6M
$63.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$106.6M
Total Assets
$359.1M
$118.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
PKE
PKE
Q4 25
$74.6M
$63.6M
Q3 25
$58.8M
$61.6M
Q2 25
$78.2M
$65.6M
Q1 25
$51.3M
$68.8M
Q4 24
$55.5M
$70.0M
Q3 24
$59.6M
$72.0M
Q2 24
$73.1M
$74.4M
Q1 24
$89.7M
$77.2M
Stockholders' Equity
CCCC
CCCC
PKE
PKE
Q4 25
$256.6M
$106.6M
Q3 25
$154.4M
$105.8M
Q2 25
$174.1M
$105.0M
Q1 25
$195.1M
$107.2M
Q4 24
$216.0M
$107.4M
Q3 24
$242.7M
$110.3M
Q2 24
$247.1M
$111.7M
Q1 24
$258.3M
$112.9M
Total Assets
CCCC
CCCC
PKE
PKE
Q4 25
$359.1M
$118.1M
Q3 25
$265.5M
$116.4M
Q2 25
$296.5M
$120.7M
Q1 25
$319.5M
$122.1M
Q4 24
$349.6M
$124.2M
Q3 24
$376.1M
$125.1M
Q2 24
$381.1M
$129.4M
Q1 24
$398.4M
$132.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
PKE
PKE
Operating Cash FlowLast quarter
$-22.1M
$5.1M
Free Cash FlowOCF − Capex
$4.3M
FCF MarginFCF / Revenue
24.6%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$3.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
PKE
PKE
Q4 25
$-22.1M
$5.1M
Q3 25
$-31.2M
$-2.1M
Q2 25
$-12.1M
$1.6M
Q1 25
$-33.3M
$969.0K
Q4 24
$-17.9M
$2.7M
Q3 24
$-24.1M
$1.4M
Q2 24
$-5.0M
$-423.0K
Q1 24
$-18.1M
$5.3M
Free Cash Flow
CCCC
CCCC
PKE
PKE
Q4 25
$4.3M
Q3 25
$-31.6M
$-2.3M
Q2 25
$1.1M
Q1 25
$338.0K
Q4 24
$-17.9M
$2.7M
Q3 24
$-24.1M
$1.3M
Q2 24
$-5.2M
$-435.0K
Q1 24
$5.1M
FCF Margin
CCCC
CCCC
PKE
PKE
Q4 25
24.6%
Q3 25
-281.5%
-14.0%
Q2 25
7.2%
Q1 25
2.0%
Q4 24
-346.5%
18.6%
Q3 24
-157.2%
7.5%
Q2 24
-43.1%
-3.1%
Q1 24
31.4%
Capex Intensity
CCCC
CCCC
PKE
PKE
Q4 25
4.8%
Q3 25
3.7%
1.1%
Q2 25
3.1%
Q1 25
3.7%
Q4 24
0.1%
0.4%
Q3 24
0.1%
1.2%
Q2 24
1.6%
0.1%
Q1 24
0.0%
1.0%
Cash Conversion
CCCC
CCCC
PKE
PKE
Q4 25
1.73×
Q3 25
-0.88×
Q2 25
0.76×
Q1 25
0.78×
Q4 24
1.73×
Q3 24
0.70×
Q2 24
-0.43×
Q1 24
1.98×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CCCC
CCCC

Segment breakdown not available.

PKE
PKE

North America$16.8M97%
Other$546.0K3%

Related Comparisons